132 related articles for article (PubMed ID: 35578359)
21. Pericardial tamponade during pembrolizumab treatment in a patient with advanced lung adenocarcinoma: A case report and review of the literature.
Harada K; Ogasawara M; Shido A; Meno A; Oda S; Yoshida S; Yoshida S; Yoshikawa A; Ebata K; Abiko S; Kawagishi N; Sano I; Oda H; Miyagishima T
Thorac Cancer; 2020 May; 11(5):1350-1353. PubMed ID: 32181993
[TBL] [Abstract][Full Text] [Related]
22. Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China Study.
Wu YL; Zhang L; Fan Y; Zhou J; Zhang L; Zhou Q; Li W; Hu C; Chen G; Zhang X; Zhou C; Dang T; Sadowski S; Kush DA; Zhou Y; Li B; Mok T
Int J Cancer; 2021 May; 148(9):2313-2320. PubMed ID: 33231285
[TBL] [Abstract][Full Text] [Related]
23. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Burtness B; Harrington KJ; Greil R; Soulières D; Tahara M; de Castro G; Psyrri A; Basté N; Neupane P; Bratland Å; Fuereder T; Hughes BGM; Mesía R; Ngamphaiboon N; Rordorf T; Wan Ishak WZ; Hong RL; González Mendoza R; Roy A; Zhang Y; Gumuscu B; Cheng JD; Jin F; Rischin D;
Lancet; 2019 Nov; 394(10212):1915-1928. PubMed ID: 31679945
[TBL] [Abstract][Full Text] [Related]
24. A potential mechanism of the onset of immune-related pneumonitis triggered by anti-PD-1 treatment in a patient with advanced adenocarcinoma lung cancer: case report.
Feng Y; Chen C; Zhao L; Zhu X; Zhu X; Li Q
BMC Pulm Med; 2021 Sep; 21(1):291. PubMed ID: 34521373
[TBL] [Abstract][Full Text] [Related]
25. [Successful treatment results of S-1 administration in 2 patients, one with a remnant tumor of the larynx and metastatic tumors to the lung, and another with a metastatic tumor in the neck from the hypopharynx].
Abo H; Tsukuda M; Matsuda H; Horiuchi C; Taguchi T; Watanabe M; Niho T
Gan To Kagaku Ryoho; 2009 Oct; 36(10):1707-9. PubMed ID: 19838032
[TBL] [Abstract][Full Text] [Related]
26. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Cohen EEW; Soulières D; Le Tourneau C; Dinis J; Licitra L; Ahn MJ; Soria A; Machiels JP; Mach N; Mehra R; Burtness B; Zhang P; Cheng J; Swaby RF; Harrington KJ;
Lancet; 2019 Jan; 393(10167):156-167. PubMed ID: 30509740
[TBL] [Abstract][Full Text] [Related]
27. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
Gadgeel S; Rodríguez-Abreu D; Speranza G; Esteban E; Felip E; Dómine M; Hui R; Hochmair MJ; Clingan P; Powell SF; Cheng SY; Bischoff HG; Peled N; Grossi F; Jennens RR; Reck M; Garon EB; Novello S; Rubio-Viqueira B; Boyer M; Kurata T; Gray JE; Yang J; Bas T; Pietanza MC; Garassino MC
J Clin Oncol; 2020 May; 38(14):1505-1517. PubMed ID: 32150489
[TBL] [Abstract][Full Text] [Related]
28. 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer.
Borghaei H; Langer CJ; Gadgeel S; Papadimitrakopoulou VA; Patnaik A; Powell SF; Gentzler RD; Martins RG; Stevenson JP; Jalal SI; Panwalkar A; Yang JC; Gubens M; Sequist LV; Awad MM; Fiore J; Saraf S; Keller SM; Gandhi L
J Thorac Oncol; 2019 Jan; 14(1):124-129. PubMed ID: 30138764
[TBL] [Abstract][Full Text] [Related]
29. Pemetrexed maintenance with or without pembrolizumab in non-squamous non-small cell lung cancer: A cross-trial comparison of KEYNOTE-189 versus PARAMOUNT, PRONOUNCE, and JVBL.
Garon EB; Kim JS; Govindan R
Lung Cancer; 2021 Jan; 151():25-29. PubMed ID: 33285468
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L).
Miyawaki T; Kenmotsu H; Harada H; Ohde Y; Chiba Y; Haratani K; Okimoto T; Sakamoto T; Wakuda K; Ito K; Uemura T; Sakata S; Kogure Y; Nishimura Y; Nakagawa K; Yamamoto N
BMC Cancer; 2021 Oct; 21(1):1121. PubMed ID: 34663250
[TBL] [Abstract][Full Text] [Related]
31. Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.
Levy BP; Giaccone G; Besse B; Felip E; Garassino MC; Domine Gomez M; Garrido P; Piperdi B; Ponce-Aix S; Menezes D; MacBeth KJ; Risueño A; Slepetis R; Wu X; Fandi A; Paz-Ares L
Eur J Cancer; 2019 Feb; 108():120-128. PubMed ID: 30654297
[TBL] [Abstract][Full Text] [Related]
32. Major pathological response and durable locoregional control after neoadjuvant pembrolizumab-carboplatin-paclitaxel in head and neck cancer.
Cabezas-Camarero S; Alonso-Ovies A; Merino-Menéndez S; Cabrera-Martín MN; Plaza-Hernández JC; Pérez-Segura P
Oral Oncol; 2021 Dec; 123():105589. PubMed ID: 34742008
[TBL] [Abstract][Full Text] [Related]
33. Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population.
Chen WC; Chu PY; Lee YT; Lu WB; Liu CY; Chang PM; Yang MH
Medicine (Baltimore); 2017 Dec; 96(52):e9519. PubMed ID: 29384959
[TBL] [Abstract][Full Text] [Related]
34. Carboplatin and Pembrolizumab Chemoimmunotherapy Achieves Remission in Recurrent, Metastatic Sebaceous Carcinoma.
Kodali S; Tipirneni E; Gibson PC; Cook D; Verschraegen C; Lane KA
Ophthalmic Plast Reconstr Surg; 2018; 34(5):e149-e151. PubMed ID: 29979269
[TBL] [Abstract][Full Text] [Related]
35. Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040.
Harrington KJ; Soulières D; Le Tourneau C; Dinis J; Licitra LF; Ahn MJ; Soria A; Machiels JH; Mach N; Mehra R; Burtness B; Ellison MC; Cheng JD; Chirovsky DR; Swaby RF; Cohen EEW
J Natl Cancer Inst; 2021 Feb; 113(2):171-181. PubMed ID: 32407532
[TBL] [Abstract][Full Text] [Related]
36. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
[TBL] [Abstract][Full Text] [Related]
37. A Randomized Phase III Study of Pembrolizumab Versus Pembrolizumab-Carboplatin-Pemetrexed for Locally Advanced or Metastatic Nonsquamous Non-small-cell Lung Cancer with PD-L1 50% or more (LAPLACE-50): Study Protocol.
Kogure Y; Hashimoto H; Oki M
Clin Lung Cancer; 2021 Nov; 22(6):e921-e924. PubMed ID: 34053861
[TBL] [Abstract][Full Text] [Related]
38. The Role of Immunotherapy and Radiation Therapy in Tumor Chemosensitivity in Advanced Head and Neck Cancer.
Atiq SO; Atiq OO; Atiq MO; Phillips KC; Jacks BB; Moreno M; Maraboyina S; Atiq OT
Am J Case Rep; 2018 Oct; 19():1241-1244. PubMed ID: 30333474
[TBL] [Abstract][Full Text] [Related]
39. [Two head and neck cancer patients who responded to chemotherapy consisting of only TS-1].
Mikami Y; Tsukuda M; Kawai S; Kagesato Y; Tanigaki Y; Horiuchi C; Mochimatsu I
Gan To Kagaku Ryoho; 2003 Oct; 30(10):1473-7. PubMed ID: 14584280
[TBL] [Abstract][Full Text] [Related]
40. FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.
Larkins E; Blumenthal GM; Yuan W; He K; Sridhara R; Subramaniam S; Zhao H; Liu C; Yu J; Goldberg KB; McKee AE; Keegan P; Pazdur R
Oncologist; 2017 Jul; 22(7):873-878. PubMed ID: 28533473
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]